reports
Dime Community Bancshares Declares Quarterly Cash Dividend for Series ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series A Preferred Stock HAUPPAUGE, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM, DCOMP and DCOMG) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.34375 per share on the Company’s 5.50% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on May 15, 2025 to holders of record as of May 8, 2025. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York...
Dime Community Bancshares, Inc. Reports First Quarter 2025 EPS of $0.4...
Dime Community Bancshares, Inc. Reports First Quarter 2025 EPS of $0.45; Adjusted EPS of $0.57 Continued Growth in Core Deposits and Business Loans On a Year-over-Year Basis Net Interest Margin Expands by 16 basis points on a Linked Quarter Basis to 2.95% HAUPPAUGE, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $19.6 million for the quarter ended March 31, 2025, or $0.45 per diluted common share, compa...
Dime Announces Plans to Enter Lakewood, New Jersey
Dime Announces Plans to Enter Lakewood, New Jersey HAUPPAUGE, N.Y., April 17, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today announced that its Board of Directors has approved a plan to expand into Lakewood, New Jersey. A location for a full-service, free-standing branch has been identified. Management expects construction of the branch to take place in the second half of 2025, simultaneous with the regulatory approval process. The current plan is for a branch opening in e...
Dime Continues to Execute Growth Plan With Hire of Deposit-Focused Gro...
Dime Continues to Execute Growth Plan With Hire of Deposit-Focused Group George Taitt to join as Group Director, Amy Grandy to join as Associate Group Director HAUPPAUGE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired a deposit-focused Group that will cover the Queens market. The Group will be led by George Taitt and Amy Grandy. The Group was previously employed with the former Signature Bank and its successor, Flagstar Bank. Stuart H. L...
Dime Community Bancshares to Release Earnings on April 22, 2025
Dime Community Bancshares to Release Earnings on April 22, 2025 HAUPPAUGE, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the "Company") today announced that the Company expects to release its earnings for the quarter ended March 31, 2025 before the open of the U.S. equity markets on Tuesday, April 22, 2025. The Company will conduct a conference call at 8:30 a.m. (ET) on Tuesday, April 22, 2025, during which President and Chief Executive Officer (“CEO”), Stuart Lubow, will discuss the Company’s first quarter financial performance. There will be a ...
Outlook Therapeutics® Announces Acceptance of Biologics License Applic...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 ISELIN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), t...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock HAUPPAUGE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on April 24, 2025 to common stockholders of record as of April 17, 2025. The Company continues its trend of uninterrupted dividends. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust c...
Dime Expands Lending Presence on Long Island
Dime Expands Lending Presence on Long Island HAUPPAUGE, N.Y., March 21, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced that it has hired Antonia (Toni) Badolato as Senior Vice President and Group Leader. Toni comes to Dime from M&T Bank where she held the position of Senior Vice President, Group Manager. “I joined Dime given the organization’s commitment to growing their business lending presence. Dime’s ability to respond to customers quickly, combined with a flat organiz...
Dime Announces Expansion in Manhattan With Hire of Jim LoGatto
Dime Announces Expansion in Manhattan With Hire of Jim LoGatto Dime Continues to be the Bank-of-Choice for Talented Bankers HAUPPAUGE, N.Y., March 18, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced today that Jim LoGatto has joined the Company as an Executive Vice President. LoGatto will be responsible for growing Dime’s commercial banking business in Manhattan. Most recently, LoGatto served as Executive Vice President and Director of US Private Banking at Israel Discou...
Outlook Therapeutics® Re-Submits Biologics License Application for ONS...
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ...
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline an...
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and bus...
Tom Geisel to Join Dime’s Senior Executive Leadership Team
Tom Geisel to Join Dime’s Senior Executive Leadership Team Significantly Advances Dime’s Growth Plan HAUPPAUGE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), announced today that Thomas X. Geisel will join Dime as Senior Executive Vice President of Commercial Lending. Mr. Geisel will be responsible for the continued buildout and diversification of Dime’s commercial lending business. Stuart H. Lubow, President and CEO said, "Dime has had tremendous success growing ...
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ...
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced it participated in the Virtual Investor . As part of the event, Lawrence A. Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlo...
Outlook Therapeutics® Reports Financial Results for First Quarter Fisc...
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmi...
Outlook Therapeutics® Participates in Virtual Investor “What This Mean...
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial ISELIN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Jennifer Kissner, Ph.D., SVP Clinical...
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the B...
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will rema...
Dime Announces Continued Partnership with Island Harvest in 2025
Dime Announces Continued Partnership with Island Harvest in 2025 HAUPPAUGE, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that it will continue its role as a partner with Island Harvest for the 4th consecutive year. Island Harvest is Long Island’s leading hunger-relief organization. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust company with over $...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series ...
Dime Community Bancshares Declares Quarterly Cash Dividend for Series A Preferred Stock HAUPPAUGE, N.Y., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM, DCOMP and DCOMG) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.34375 per share on the Company’s 5.50% Fixed-Rate Non-Cumulative Perpetual Preferred Stock, Series A, payable on February 13, 2025 to holders of record as of February 6, 2025. ABOUT DIME COMMUNITY BANCSHARES, INC. Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a...
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Re...
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safetyONS-5010 demonstrated to be non-inferior to Lucentis at 4 and 12 weeksCompany on track for anticipated BLA resubmission in calendar Q1 2025 ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical co...
Dime Community Bancshares, Inc. Reports Fourth Quarter 2024 Results
Dime Community Bancshares, Inc. Reports Fourth Quarter 2024 Results Strong Growth in Deposits, Business Loans and Capital Ratios on a Year-Over-Year Basis Net Interest Margin Expands by 29 basis points on a Linked Quarter Basis to 2.79% HAUPPAUGE, N.Y., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”), today reported net income available to common stockholders of $21.8 million for the year ended December 31, 2024, or $0.55 per diluted common share, compared to net income...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.